Clinical trials: aldesleukin
HIV Infections
A Study to Evaluate the Effects of Giving IL-2 Alone to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3 Who Do Not Wish to Receive Anti-HIV Therapy
The purpose of this study is to evaluate the safety and tolerability of giving interleukin-2 (IL-2) alone to HIV-positive patients with CD4 cell counts greater than 350 cells/mm3 who do not wish to receive anti-HIV…
- Trial name
- NCT00000909
- Testing
- Aldesleukin
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Metastatic Renal Cell Carcinoma, Metastatic Melanoma
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
The purpose of this registry is to collect information on patients who are receiving treatment with Proleukin in an organized way, and to learn more about patient care during and after treatment.
- Trial name
- NCT01415167
- Where
- 45 sites in United States
- Volunteers
- 1,690 people
- Sponsor
- Prometheus Laboratories
Gastrointestinal Cancer, Pancreatic Cancer
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
Background: A new cancer therapy takes white blood cells from a person, grows them in a lab, genetically changes them, then gives them back to the person.
- Conditions
- Gastrointestinal Cancer, Pancreatic Cancer, Gastric Cancer, Colon Cancer
- Trial name
- NCT03745326
- Testing
- Cyclophosphamide, Fludarabine, Aldesleukin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Type 1 Diabetes
Regulatory T Cells in Type 1 Diabetes Patients Treated With IL-2
Type 1 diabetes is the most common severe chronic autoimmune disease worldwide and is caused by the autoimmune (loss of self tolerance) mediated destruction of the insulin producing pancreatic beta cells thus leading to insulin…
- Trial name
- DILT1D (NCT01827735)
- Testing
- Aldesleukin (Proleukin)
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Recurrence Tumor, Metastatic Cancer
Immunotherapy for the Treatment of Advanced Solid Tumor
The purpose of this study is to evaluate the safety, side effects and benefits of autologous tumor infiltrating lymphocytes (TIL) specific to personalized Neo-antigens in the treatment of patients with recurrent, metastatic and…
- Conditions
- Recurrence Tumor, Metastatic Cancer, Solid Tumor
- Trial name
- NCT03658785
- Testing
- TIL, Aldesleukin, Cyclophosphamide
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tongji Hospital
Kidney Cancer, Melanoma (Skin)
Biological Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies, including interferon alfa, interleukin-2, and tumor…
- Conditions
- Kidney Cancer, Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00002733
- Testing
- aldesleukin, recombinant interferon alfa, therapeutic tumor infiltrating lymphocytes
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Hoag Memorial Hospital Presbyterian
Anaplastic Astrocytoma, Anaplastic Ependymoma
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Meningioma, Anaplastic Oligodendroglioma
- Trial name
- NCT01082926
- Testing
- therapeutic allogeneic lymphocytes, aldesleukin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- City of Hope Medical Center
Locally Advanced Cervical Carcinoma, Locally Advanced Colorectal Carcinoma
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
This phase I trial tests the safety and side effects of STIL101 for injection and how well it works in treating patients with pancreatic cancer, colorectal cancer (CRC), renal cell cancer (RCC), cervical cancer (CC) and melanoma…
- Conditions
- Locally Advanced Cervical Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma
- Trial name
- NCT06626256
- Testing
- Aldesleukin, Biopsy, Biospecimen Collection
- Sponsor
- City of Hope Medical Center
Pleural Mesothelioma
TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients
This is a phase I and II clinical study for patients with malignant pleural mesothelioma (a type of cancer affecting the lining of the lung).
- Trial name
- NCT02414945
- Testing
- Cyclophosphamide, Fludarabine, Autologous tumor infiltrating lymphocytes (TILs)
- Where
- Canada
- Volunteers
- 9 people
- Sponsor
- University Health Network, Toronto
Crohn's Disease
Autologous Stem Cell Transplant for Refractory Crohn's Disease
Crohn's disease is an 'auto-immune' disorder of the gut. In this condition the body's own immune system is fighting its gut and causing inflammation and other symptoms.
- Trial name
- NCT02676622
- Testing
- mobilization of stem cells to prepare for Leukapheresis, Leukapheresis- Collection of stem cells, Preparative regimen 4-6 weeks after Leukapheresis
- Sponsor
- Nationwide Children's Hospital
Leukemia, Myeloid, Acute
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
This phase I/2 trial studies the side effects and best dose of activated natural killer cells in treating patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes.
- Trial name
- NCT01898793
- Testing
- Fludarabine, Cyclophosphamide, Leukapheresis
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Washington University School of Medicine
Type1 Diabetes
Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD)
The main purpose of this study is to see if a drug called aldesleukin, can preserve insulin production in children and young adults recently diagnosed with type 1 diabetes.
- Trial name
- ITAD (NCT03782636)
- Testing
- Aldesleukin
- Where
- 5 sites in United Kingdom
- Volunteers
- 41 people
- Sponsor
- University of Oxford
Macrophage Activation Syndrome
Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome（MAS）
The investigators evaluate the effectiveness and safeness of low-dose Recombinant Human Interleukin-2 （rhIL-2） for MAS.
- Trial name
- NCT02569463
- Testing
- Interleukin-2
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Peking University People's Hospital
Metastatic Ocular Melanoma, Metastatic Uveal Melanoma
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving…
- Trial name
- NCT01814046
- Testing
- Aldesleukin, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Purpura, Schoenlein-Henoch
The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 in Children With Henoch-schönlein Purpura
The study aims to explore the therapeutic value and mechanism of Interleukin-2 on children with Henoch-schönlein purpura.
- Trial name
- HSP (NCT04387942)
- Testing
- IL-2
- Where
- China
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- The First Hospital of Jilin University
Melanoma
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
The goal of the Phase I part of this clinical research study is to find the highest tolerable dose of vemurafenib and Aldesleukin (interleukin-2) that can be given in combination with interferon alfa-2b in patients with advanced…
- Trial name
- NCT01603212
- Testing
- Vemurafenib, IL-2, Interferon Alpha-2b
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Myeloid, Acute
A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)
This study will find the highest acceptable treatment dose of cord blood, culture expanded natural killer (NK) cells, a kind of immune cell, in patients with relapsed and/or refractory acute myeloid leukemia.
- Trial name
- NCT02781467
- Testing
- PNK-007, Cyclophosphamide, Fludarabine
- Where
- 7 sites in United States
- Volunteers
- 10 people
- Sponsor
- Celularity Incorporated
Melanoma (Skin)
Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Vaccines made from melanoma cells may make the body build an immune response to kill tumor cells. Biological therapies such as interferon gamma and interleukin-2 use different ways to stimulate the immune system and…
- Trial name
- NCT00006113
- Testing
- MART-1 antigen, aldesleukin, gp100 antigen
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Southern California
Melanoma Stage III, Melanoma Stage IV
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
The purpose of this study is to find out if the administration of Interleukin-2 concurrently with ipilimumab followed by Nivolumab will result in improved anti-cancer activity and if it is effective for advanced melanoma.
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Inoperable Disease
- Trial name
- NCT04562129
- Testing
- Interleukin-2, Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
This phase Ib/II trial studies the side effects and best dose of bispecific antibody armed activated T-cells when given together with aldesleukin and sargramostim and to see how well they work in treating patients with pancreatic…
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT02620865
- Testing
- Aldesleukin, Antibody Therapy, Fluorouracil
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute